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Abstract
The mass defect of a substance can be used in mass spectral analysis to identify peaks as likely
belonging to a compound class, such as peptides, if the mass defect is within the known range for
that compound class. For peptides, a range of possible mass defects was calculated previously, using
a set of theoretical peptides, where all possible amino acid combinations were considered (Mann, M.
Abstract from the 43rd Annual Conference on Mass Spectrometry and Allied Topics; 1995, ASMS).
We compare that range of theoretical peptide mass defects to new values obtained from in silico
tryptic digests of proteins that are abundant in human serum and human seminal fluid. The range of
mass defect values encompassing 95% of peptides for the human protein data sets was found to be
up to 50% smaller than the previously reported mass defect range for the theoretical peptides. The
smaller range established for human tryptic peptides can be used to improve peptide mass defect
filters by excluding more species that are not likely to be peptides, thus improving filter selectivity
for peptides during proteomic data analysis.
Keywords
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INTRODUCTION
Mass spectral data analysis can be a daunting task, but peak identification can be enhanced by
incorporating mass defect (MD) analysis into the work flow. MD analysis is used to predict
the elemental composition and the identification of organic compounds,1 metabolites,2–4 and
petrochemicals,5,6 by using values that are explicit to each class of substances. The elemental
composition of some peptides can be determined using MD calculations, but the utility of the
method is generally limited to smaller peptides (<800 Da).7 MD analysis is also used to identify
and classify multiple types of peptide modifications, such as phosphorylation8–10 or cross-
linking.11 Peptide MD can also be used to deconvolute overlapping peaks,12 support charge
state determination algorithms,13 and assist in high throughput protein identification, such as
in peptide mass fingerprinting (PMF) techniques. PMF data analysis can be enhanced by
excluding extrinsic peaks from analysis, whereas those peaks arise from substances other than
the protein(s) of interest.14–15 Masses are excluded, or filtered, when the MD value is not
within the window that is characteristic for that analyte. The expected window, or range, of
mass defect values for peptides is established from theoretical peptide masses. This range is
known to encompass only selected regions, or “clusters” on the mass scale.16–18 The values
in between the clusters, referred to as the “forbidden zones”, are where unmodified peptides
*To whom correspondence should be addressed. Phone: (785) 864-3015, Fax: 785-864-5396, hdesaire@ku.edu.
SUPPORTING INFORMATION AVAILABLE: MaDPUM range equations that describe the middle 90%, 97%, and 99% of human
serum tryptic peptides. This material is available free of charge via the Internet at http://pubs.acs.org.
NIH Public Access
Author Manuscript
J Proteome Res. Author manuscript; available in PMC 2011 October 1.
Published in final edited form as:













are not found. Any peaks located within these forbidden zones are indicative of peptide
modifications or non-peptide interferents. Peptide modification can occur with functional
groups that force the total mass into the forbidden zone, so that the MD is noticeably outside
of the anticipated range for peptides, for example with iodine tags,19 or in cases of
phosphorylation.8–10 PMF experiments benefit from mass defect data filtering, as evidenced
by higher protein identification probability scores, fewer false positives, and increased number
of identified peaks.15,20–22 Improvements to peptide MD filters can be made, using data sets
with actual amino acid usage in place of theoretical peptides, because using these data will
result in more accurate peptide MD values.18,23
Herein, we calculate mass defect values for two sets of human tryptic peptides and compare
the data to theoretical peptide MD calculations. The human data sets were composed using
results from in silico tryptic digestions, which were performed on human serum and seminal
fluid proteins. Analysis of the human datasets defined the range of MD values that encompasses
the middle 95% of unmodified peptides. The breadth of this range was compared to that of the
range based on theoretical peptide calculations. Equations describing the refined MD range
are presented for use in PMF studies.
EXPERIMENTAL
Peptide Generation
Proteins that are abundant in human serum24 and human seminal fluid 25 were chosen for tryptic
peptide mass defect analysis. The sequences of the serum and seminal fluid protein sets were
collected from the UniProt Knowledgebase, using search options or published accession
numbers, respectively. Sequences containing signal peptides and propeptides were truncated
so that proteins were analyzed in their relevant forms. The sequences were imported into
ProteinProspector, version 5.1.8 Basic, and an in silico digestion was performed using the MS-
Digest function. Trypsin was chosen for the protease, multiple charges and variable
modifications to amino acids were omitted, and zero missed cleavages were allowed. Peptides
with a minimum of five amino acids and within the mass range of 500–8000 Da were chosen
for analysis.
Mass Defect Analysis
The mass defect was calculated for each tryptic peptide. The mass defect per unit mass
(MaDPUM) was then calculated by dividing the mass defect by the monoisotopic peptide mass,
and the values were sorted into 100 Da bins, based on the nominal masses of the peptides. The
mean and the range of MaDPUM values that encompassed the middle 95% of peptides were
established for each bin and plotted against the peptide mass. The MaDPUM calculations were
performed separately for the human serum and seminal fluid data sets. A third set of MaDPUM
ranges were established for theoretical peptides, based on previously published mass defect
data for theoretical peptides.16,20
Filtering Proteomics Data with MaDPUM ranges
One thousand peaks from a depleted human serum LC/MS/MS experimental file26 were
selected for analysis using the newly established MaDPUM ranges. The peaks were located
between retention time 38.00 and 43.57 and had been selected for MS/MS analysis.26 The
monoisotopic mass for each peak was collected and then classified as likely corresponding to
a human tryptic peptide or not, using the MaDPUM ranges established using human serum
peptides. The classification analysis was repeated using the MaDPUM ranges based on
theoretical peptides.
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Mass defect filters benefit proteomic data analysis by removing non-peptide peaks. The
removal is performed prior to submitting MS data to an analysis program such as MASCOT,
and is achieved by eliminating peaks whose numerical mass defect values are not within an
expected window. Peaks located in the mass ranges outside of the expected window, often
referred to as the "forbidden zone", are then excluded from further analysis.
MaDPUM Calculations
In these experiments, we defined the range of mass defect per unit mass (MaDPUM) values
that incorporates the middle 95% of tryptic peptides from two human protein data sets. The
sequences of the 50 most abundant seminal fluid proteins25 and nearly 300 human serum
proteins24 were collected from the UniProt Knowledgebase. Each protein was subjected to an
in silico tryptic digestion using the MS-Digest function within ProteinProspector. The outputs
were used to calculate the mass defect (MD) for each peptide (equation I), which is defined as
the difference between the nominal (NM) and monoisotopic masses (MI).1 Nominal mass is
an integer sum consisting of the integer masses of the most abundant isotopes for each element,
e.g. C = 12, H = 1, and O = 16.27 The monoisotopic mass is a sum of the exact masses of the
most abundant isotope for each element in the sample of a substance, e.g. C = 12.0000, H =
1.0078, O = 15.9949.27 The MaDPUM was calculated by dividing the mass defect by the




The peptides within the human serum data set were grouped into 100 Da bins for analysis,
according to the original nominal mass of the peptide. Within each 100 Da bin, the mean
MaDPUM value was calculated. The global mean was then calculated and determined to be
0.00050 for the serum data set. In Figure 1a, the MaDPUM mean values are plotted for each
nominal mass 100 Da bin for serum peptides. The mean MaDPUM value of 0.00050 is higher
than the literature value of 0.00048,16,20 which incorporates theoretical peptide compositions.
Since analysis of the human serum tryptic peptides produced results that differ from the
literature values, the set of human seminal fluid peptides was analyzed as a second data set, to
validate that the observations were not characteristic of human serum peptides alone. This data
is shown in Figure 1b. The seminal fluid data set also showed that the global mean value was
0.00050, the same as the human serum data set. The agreement in these two data sets suggests
that this mean mass defect value (0.00050) is appropriate to use for any large set of human
proteins.
In Figure 1, the smallest peptides are noted to have a mean MaDPUM value greater than the
average due to a mathematical bias that is based on protease specificity.28 All tryptic peptides,
except possibly the C-terminal peptide, possess an R or K residue at the peptide’s C-terminus.
29 The MaDPUM for both R and K is greater than the average MaDPUM for all common amino
acids, thus creating a slight bias for an increased MaDPUM for the small tryptic peptides.
Peptides with missed cleavages were purposely excluded from this study, as the missed
cleavage peptides will be larger and thus possess a mass defect value that shows little effect
from the mathematical R or K bias that is evident in small peptides.
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To understand why global mean values for both the serum and seminal fluid data was larger
than anticipated (0.00050 instead of 0.00048), the peptide compositions, including amino acid
usage, were analyzed in the seminal fluid data. The theoretical peptide data set is comprised
of peptides where the 20 common amino acids are utilized equally, accounting for 5% of each
peptide. In Figure 2, amino acid usage is shown, as calculated for the seminal fluid data set,
ranked by increasing usage. The MaDPUM value for each amino acid is indicated by bar height.
The ten amino acids to the right, in Figure 2, would be expected to comprise 50.0% of
polypeptide compositions if each amino acid were used equally, but instead they account for
65.8% of amino acid usage in the seminal fluid data. The five least utilized amino acids, to the
left in the figure, have MaDPUM values less than the average for amino acids. These
observations demonstrate that amino acid usage will determine the MaDPUM value for each
peptide, and the differential amino acid utilization also forces the global average MaDPUM
value to 0.00050, higher than previously reported. These results are consistent with Wolski et
al., who also demonstrated, using computational methods, that accounting for amino acid usage
shifts the MaDPUM to >0.480.30 Amino acid usage clearly is an important consideration when
refining mass defect filters for peptides, as usage varies across species.31
MaDPUM Width for Theoretical Peptides
The theoretical peptide masses and corresponding MaDPUM values were calculated using
relationships based on nominal peptide mass, as described previously.16,20
(III)
(IV)
The MI (monoisotopic) masses for theoretical peptides were generated using equation III, and
the width (W) of the range that encompassed 95% of peptides was determined using equation
IV.16,20 We used these equations to calculate MaDPUM for the theoretical peptides, for each
100 Da bin. Results were plotted against nominal peptide mass (Figure 3a). These data are used
to assess how similar the width is for the experimental MaDPUM data.
MaDPUM Width (range) for Human Biofluid Peptides
Extensive studies of the width, or the range, of mass defect values for unmodified peptides
were conducted on both the serum and seminal fluid proteins. These results indicated that no
differences existed between the two human data sets for the range of MaDPUM values
encompassing the middle 95% of peptides. The width (range) determination studies below are
presented exclusively using the serum peptides, as that set has more data points
After calculating the mass defect for each serum peptide in each 100 Da bin, we measured the
mass defect width for the biofluid data, which can be defined as a range of MaDPUM values
that incorporated 95% of all the human serum peptides, for each 100 Da bin. This width was
calculated at each 100 Da bin by sorting the MaDPUM values in ascending order within the
bin, and by manually observing the middle 95% of values. The yellow area in the center of
Figure 3a represents the experimental width. The red areas in Figure 3a represent MaDPUM
values that are excluded from the serum data’s width, but are included in the theoretical width,
according to equation IV.
In Figure 3b, the data is plotted differently. Here, MD values are plotted vs. nominal peptide
mass divided into 100 Da bins. The MD widths are shown for the theoretical peptides (in red)
and the human serum peptides (in the center shown in yellow). The theoretical peptide width
Toumi and Desaire Page 4













was established using equation IV. The width for the serum peptides was defined using the
experimental data to determine data points for the upper and lower boundaries containing 95%
of peptides within each 100 Da bin. In figure 3b, symbols indicate the individual data points
for each bin, and linear trend lines to fit the data points are shown. Equations that define the
upper and lower boundary best fit lines are found in equations V and VI below, respectively.
(V)
(VI)
The R2 values for the best fit lines are 0.99921 or greater.
Width Analysis
The differences in width between the human serum data set and the theoretical data were
analyzed to determine how significantly this data will affect the size of MD mass analysis
filters. The MaDPUM width established for theoretical peptide compositions are significantly
wider than the width in this study on human serum and seminal fluid tryptic peptides. For
peptides with a mass of 1000 Da, the width of MaDPUM values that would include the middle
95% of serum peptides is 42.3% smaller than the width established using theoretical peptides.
See Table 1. At a mass of 3000 Da, the difference in width is smaller, 25.6%. These differences
in the calculated size of the “forbidden zone” for mass defect analysis are largest where it makes
the most impact, on the lower end of the mass scale; a majority of tryptic peptides are less than
3000 Da in mass.32 The differences in width indicate that a significant number of additional
peaks may be excluded from analysis, without losing data from unmodified peptides.
Filtering Proteomics Data with MaDPUM Equations
One thousand peaks from a human serum LC/MS/MS file26 were collected and then filtered
using the MaDPUM ranges established from human serum tryptic peptides. Of the 1,000
masses selected for filtering, 268, or 26.8%, were excluded (or filtered) because the mass defect
values did not correspond to that of an unmodified human tryptic peptide. When the theoretical
peptide range equations were used to filter the data, only 99, or 9.9%, of the peaks were
excluded. In this experiment, using the MaDPUM ranges based on human serum peptides,
described herein, produced a three-fold increase in the number of non-peptide peaks that can
be excluded from further data analysis.
CONCLUSIONS
To refine peptide mass defect filters, the mass defect and mass defect per unit mass (MaDPUM)
values were analyzed for two sets of human proteins and compared to data from the literature
based on theoretical peptide compositions. The global human MaDPUM mean value was found
to be 0.00050, larger than previously reported, and analysis of amino acid usage indicates that
organism usage should be considered when refining mass defect filters for peptide analysis.
The width of MaDPUM values encompassing 95% of peptides within the data sets analyzed
were found to be up to 50% smaller than the width previously established using the theoretical
peptide data. The selectivity of peptide mass defect filters can be improved by using the refined
equations presented here, describing the upper and lower boundaries of the mass defect values
for unmodified peptides. Use of these equations increase the number of excluded extraneous
(non-peptide or modified peptide) peaks.
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MaDPUM mean values as calculated for each nominal peptide mass 100 Da bin. Global mean
for both (a) human serum peptides and (b) human seminal fluid peptides was determined at
0.00050, indicated by the dark, horizontal line.
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Amino acid usage for the 20 common amino acids. The MaDPUM value for each amino
acid is indicated by bar height in ppm. Usage is shown for the human seminal fluid data set.
The 20 common amino acids are ranked by increasing usage from left to right. The 5 least
utilized amino acids, shown in red, possess a MaDPUM value that is less than the average
value for all amino acids. Amino acid usage in human seminal fluid proteins determines the
mean MaDPUM value of 500 ppm (or 0.00050)
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Figure 3a. MaDPUM values in ppm vs. nominal peptide mass in Da. The red area represents
the values that are excluded from the human serum tryptic peptide dataset, but included in
theoretical peptide calculations. The area in yellow represents the human serum tryptic peptide
MaDPUM values. The differences in MaDPUM widths for the nominal masses shown were
found to be between 23–50% for the analyzed mass range.
Figure 3b. Mass defect vs. nominal peptide mass in Da. The area representing mass defect
values that encompass 95% of human serum tryptic peptides is yellow, which is a significantly
more narrow range of mass defect values than those corresponding to the theoretical peptide
data set, shaded in red. The upper and lower boundaries incorporating 95% of the serum
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peptides was calculated for each 100 Da bin and data points are indicated by blue symbols, ▲
upper boundary and ■ lower boundary. Best fit lines through the points were added to the data,
and the equations can be found in equations V and VI for the upper and lower boundaries of
the serum peptides.
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Table 1
Observed MaDPUM ranges for peptide data sets. Where ws = width of the observed MaDPUM range for human
serum tryptic peptides, wt = width of the observed MaDPUM range for theoretical peptides. The MaDPUM
values are presented in ppm.
Peptide Mass (Da) MaDPUMws MaDPUMwt Size Difference
1000 162 281 42.3%
2000 132 193 31.6%
3000 114 162 25.6%
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